> ## Content Index
> Fetch the complete content index at: https://adjacent.media/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 Drugs Will Soon Target Wellness, Not Just Weight
- URL: https://adjacent.media/signals/glp-1-drugs-will-soon-target-wellness-not-just-weight/
- Published: 2026-08-10T23:05:40.000Z
- Updated: 2026-08-10T23:05:40.000Z
- Description: Galloway is claiming the market for semaglutide and tirzepatide will expand beyond obesity into preventive health and performance enhancement. If true, these drugs shift from niche pharmaceuticals to mass-market wellness products.
- Author: Jonathan Greene
- Tags: #signal, theme-consumer, health trends, consumer behavior, wellness adoption

Source: [Scott Galloway](https://open.substack.com/pub/profgmedia/p/take-a-break)

Galloway is claiming the market for semaglutide and tirzepatide will expand beyond obesity into preventive health and performance enhancement. If true, these drugs shift from niche pharmaceuticals to mass-market wellness products. The consequence: pharmaceutical companies, not fitness or nutrition brands, own the longevity category. A single drug class becomes normalized like vitamins or statins. The competition then moves to distribution and messaging control as GLP-1s become infrastructure rather than treatment.